Qor Growth Leverage BenevolentAI’s Qor decision intelligence platform to win biotech and pharma customers with pilot licensing and enterprise deployment. Focus use cases on target identification, literature synthesis, and trial optimization to accelerate R&D decision-making and time-to-value. Offer data integration and customization to fit clients’ data ecosystems.

ROI Partnerships With a strong funding runway and modest revenue, emphasize ROI-driven engagements and cost-sharing pilots. Propose outcome-based pricing and co-development deals to align incentives and shorten sales cycles, leveraging existing success stories to de-risk purchases.

Strategic Leadership Recent leadership changes signal a sharpened focus on scalable growth and financial discipline. Position BenevolentAI as a strategic partner for long-term AI-enabled drug discovery programs, offering board-ready business cases and tailored go-to-market plans for enterprise customers.

EMEA Focus US footprint downsizing makes the UK and Europe the primary growth corridors. Target London, Cambridge, and other European biotech clusters for partnerships, pilots, and regional support, while offering flexible delivery models aligned with local regulations and customers’ budgets.

Proof of Value Historical impact, such as identifying baricitinib as a potential Covid-19 treatment quickly, provides a strong credibility signal. Use this success as a reference in marketing and sales materials, and offer explainable AI outputs that satisfy regulatory and scientific scrutiny.